Related Experiment Video
Updated: Jul 29, 2025

Multi-Faceted Mass Spectrometric Investigation of Neuropeptides in Callinectes sapidus
Published on: May 31, 2022
Dynorphin 1-17 biotransformation peptides: properties, challenges and solutions for future therapeutics development
Rama Ballouze1, Salizawati Muhamad Salhimi1, Noratiqah Mohtar1
1School of Pharmaceutical Sciences, Universiti Sains Malaysia, USM, Penang, 11800, Malaysia.
Abstract:
It is well established that endogenously produced dynorphin 1-17 (DYN 1-17) is susceptible to enzymatic degradation, producing a variety of unique fragments in different tissue matrices and disease pathologies. DYN 1-17 and its major biotransformation fragments have significant roles in neurological and inflammatory disorders upon interacting with opioid and non-opioid receptors at both central and peripheral levels, thus highlighting their potential as drug candidates. Nevertheless, their development as promising therapeutics is challenged by several issues. This review aims to provide the latest and comprehensive updates on DYN 1-17 biotransformed peptides, including their pharmacological roles, pharmacokinetic studies and relevant clinical trials. Challenges in their development as potential therapeutics and proposed solutions to overcome these limitations are also discussed.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Biotransformation: Overview
Opioid Receptors: Overview
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management

